loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Atosiban

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Atosiban

    ACTIVE PHARMA INGREDIENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 417,144Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EU Moment of Truth For Abaloparatide & Advanced Therapy Tab-Cel
    EU Moment of Truth For Abaloparatide & Advanced Therapy Tab-Cel

    11 Oct 2022

    // PHARMAINTELLIGENCE

    https://pink.pharmaintelligence.informa.com/PS147138/EU-Moment-of-Truth-For-Abaloparatide--Advanced-Therapy-TabCel

    PHARMAINTELLIGENCE
    11 Oct 2022
    Share Share
    Quince Presents Data Demonstrating Application of Bone-targeting Platform
    Quince Presents Data Demonstrating Application of Bone-targeting Platform

    12 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220912005365/en

    BUSINESSWIRE
    12 Sep 2022
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Tymlos (Abaloparatide)
    FDA Confirms Paragraph IV Patent Litigation for Tymlos (Abaloparatide)

    24 Aug 2022

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-tymlos-abaloparatide-1661948708.pdf

    FDA
    24 Aug 2022
    Share Share
    Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA
    Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA

    11 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220811005185/en

    BUSINESSWIRE
    11 Aug 2022
    Share Share
    2 investment firms buy Radius, bone drug Tymlos for $890M
    2 investment firms buy Radius, bone drug Tymlos for $890M

    24 Jun 2022

    // Kevin Dunleavy FIERCEPHARMA

    https://www.fiercepharma.com/pharma/radius-health-bought-out-two-investment-firms-890-million

    Kevin Dunleavy FIERCEPHARMA
    24 Jun 2022
    Share Share